Literature DB >> 16641451

Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.

Jayati Mookerjee Basu1, Ananda Mookerjee, Prosenjit Sen, Suniti Bhaumik, Pradip Sen, Subha Banerjee, Ksudiram Naskar, Soumitra K Choudhuri, Bhaskar Saha, Sanghamitra Raha, Syamal Roy.   

Abstract

Pentavalent antimony complexes, such as sodium stibogluconate and sodium antimony gluconate (SAG), are still the first choice for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis, or kala-azar. Although the requirement of a somewhat functional immune system for the antileishmanial action of antimony was reported previously, the cellular and molecular mechanism of action of SAG was not clear. Herein, we show that SAG induces extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 phosphorylation through phosphoinositide 3-kinase (PI3K), protein kinase C, and Ras activation and p38 mitogen-activated protein kinase (MAPK) phosphorylation through PI3K and Akt activation. ERK-1 and ERK-2 activation results in an increase in the production of reactive oxygen species (ROS) 3 to 6 h after SAG treatment, while p38 MAPK activation and subsequent tumor necrosis factor alpha release result in the production of nitric oxide (NO) 24 h after SAG treatment. Thus, this study has provided the first evidence that SAG treatment induces activation of some important components of the intracellular signaling pathway, which results in an early wave of ROS-dependent parasite killing and a stronger late wave of NO-dependent parasite killing. This opens up the possibility of this metalloid chelate being used in the treatment of various diseases either alone or in combination with other drugs and vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641451      PMCID: PMC1472228          DOI: 10.1128/AAC.50.5.1788-1797.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.

Authors:  H W Murray; C Montelibano; R Peterson; J P Sypek
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

2.  The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls.

Authors:  O Vladimirova; F M Lu; L Shawver; B Kalman
Journal:  Inflamm Res       Date:  1999-07       Impact factor: 4.575

Review 3.  Kala-azar as an AIDS-related opportunistic infection.

Authors:  H W Murray
Journal:  AIDS Patient Care STDS       Date:  1999-08       Impact factor: 5.078

4.  Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.

Authors:  J Blanchette; N Racette; R Faure; K A Siminovitch; M Olivier
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

5.  Sodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human blood.

Authors:  S Rais; A Perianin; M Lenoir; A Sadak; D Rivollet; M Paul; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Leishmania donovani promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase-1/2 during infection of naive macrophages.

Authors:  C Privé; A Descoteaux
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

7.  SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity.

Authors:  B Cuevas; Y Lu; S Watt; R Kumar; J Zhang; K A Siminovitch; G B Mills
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

8.  Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

Authors:  H W Murray; S Delph-Etienne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

Review 9.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

10.  Therapeutic and prophylactic uses of protein A in the control of Leishmania donovani infection in experimental animals.

Authors:  A C Ghose; A Mookerjee; K Sengupta; A K Ghosh; S Dasgupta; P K Ray
Journal:  Immunol Lett       Date:  1999-02       Impact factor: 3.685

View more
  66 in total

1.  Infection of neutrophil granulocytes with Leishmania major activates ERK 1/2 and modulates multiple apoptotic pathways to inhibit apoptosis.

Authors:  Arup Sarkar; Eresso Aga; Uta Bussmeyer; Asima Bhattacharyya; Sonja Möller; Lars Hellberg; Martina Behnen; Werner Solbach; Tamás Laskay
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Leishmania donovani-induced ceramide as the key mediator of Akt dephosphorylation in murine macrophages: role of protein kinase Czeta and phosphatase.

Authors:  Ranadhir Dey; Nivedita Majumder; Surajit Bhattacharjee; Suchandra Bhattacharyya Majumdar; Rajdeep Banerjee; Sandipan Ganguly; Pradeep Das; Subrata Majumdar
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Molecular identification of an old clinical isolate of Indian Kala-azar.

Authors:  Madhumita Manna; Supriya Khanra
Journal:  J Parasit Dis       Date:  2016-06-04

Review 5.  Nitric oxide and redox mechanisms in the immune response.

Authors:  David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton
Journal:  J Leukoc Biol       Date:  2011-01-13       Impact factor: 4.962

6.  Intracellular emetic signaling cascades by which the selective neurokinin type 1 receptor (NK1R) agonist GR73632 evokes vomiting in the least shrew (Cryptotis parva).

Authors:  W Zhong; S Chebolu; N A Darmani
Journal:  Neurochem Int       Date:  2018-11-16       Impact factor: 3.921

7.  Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

Authors:  Arun Kumar Haldar; Vinod Yadav; Eshu Singhal; Kamlesh Kumar Bisht; Alpana Singh; Suniti Bhaumik; Rajatava Basu; Pradip Sen; Syamal Roy
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

8.  Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Authors:  Manu Vanaerschot; Ilse Maes; Meriem Ouakad; Vanessa Adaui; Louis Maes; Simonne De Doncker; Suman Rijal; François Chappuis; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

9.  Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.

Authors:  Anselmo S Souza; Angela Giudice; Júlia Mb Pereira; Luís H Guimarães; Amelia R de Jesus; Tatiana R de Moura; Mary E Wilson; Edgar M Carvalho; Roque P Almeida
Journal:  BMC Infect Dis       Date:  2010-07-15       Impact factor: 3.090

10.  A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells.

Authors:  Shilpak Chatterjee; Ananda Mookerjee; Jayati Mookerjee Basu; Paramita Chakraborty; Avishek Ganguly; Arghya Adhikary; Debanjan Mukhopadhyay; Sudipto Ganguly; Sudipta Ganguli; Rajdeep Banerjee; Mohammad Ashraf; Jaydip Biswas; Pradeep K Das; Gourisankar Sa; Mitali Chatterjee; Tanya Das; Soumitra Kumar Choudhuri
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.